Cyclerion Therapeutics to Host Pipeline Update Webinar
20. April 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS Neuropsychiatric key opinion leader, Andreas Reif,...
Cyclerion Therapeutics Announces Departure of Chief Medical Officer
18. März 2021 17:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
25. Februar 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers...
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
25. Januar 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company’s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 ...
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
04. Januar 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious...
Cyclerion Announces Leadership Transitions
21. Dezember 2020 07:30 ET
|
Cyclerion Therapeutics, Inc.
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor Cheryl Gault promoted to Chief Operating Officer Amy Schulman stepping down from Board of Directors ...
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
05. November 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant improvements in multiple measures associated with age-related cognitive decline and neurodegenerative...
Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
14. Oktober 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
Showed significant improvements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases Confirmed blood-brain-barrier...
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
14. Oktober 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company, today announced top-line results from its STRONG-SCD...
Cyclerion to Participate at Upcoming September 2020 Investor Conferences
04. September 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...